Table 1.
Clinicopathologic characteristics, biomarkers, initial (clinical) tumor staging and primary baseline tumor size measured by US, (post-neoadjuvant) residual gross tumor size, residual cancer burden, post-treatment tumor size measured by US, treatment regimens, and Miller-Payne (MP) grade
| Subject # | Age | Histology type | Grade1 score | Biological subtype | Tumor stage/ US tumors (cm) | Residual tumor (cm) (gross)/RCB index | US Tumor size (post) (cm) | Treatment regimen | MP grade |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| NIR005 | 40 | IDC | Intermed (6) | ER + PR + HER2− | T2/2.6 | 2.1/2.796 | 1.2 | ACT | 3 |
| NIR006 | 44 | IDC | High (9) | ER-PR-HER2− | T2/2.2 | 0.0/0.0 | 0.3 | ACT | 5 |
| NIR008 | 31 | IDC | High (9) | ER + PR + HER2− | T2/2.1 | 0.8/2.73 | 0.8 | ACT | 3 |
| NIR011 | 45 | IDC | High (9) | ER-PR-HER− | T2/2.1 | 0.0/0.0 | 1.1 | ACT | 5 |
| NIR014 | 38 | IDC | Intermed (6) | ER + PR + HER2− | T2/5.2 | 2.5/3.19 | 0.5 | ACT | 2 |
| NIR015 | 61 | IDC | High (9) | ER-PR + HER2− | T2/3.6 | 2.4/2.368 | 1.0 | ACT | 1 |
| NIR021 | 59 | IDC | High (8) | ER-PR-HER− | T1/1.0 | 0.0/0.0 | 0.4 | ACT | 5 |
| NIR023 | 65 | IDC | High (9) | ER-PR-HER2− | T2/1.9 | 0.3/1.333 | 0.7 | ACT | 3 |
| NIR025 | 59 | IDC | High (9) | ER-PR-HER2− | T3/4.6 | 0.0/0.0 | 0.4 | ACT | 5 |
| NIR026 | 45 | IDC | High (9) | ER + PR + HER2− | T2/3.1 | 0.7/1.355 | 3.4 | ACT | 4 |
| NIR027 | 41 | IDC | High (9) | ER + PR-HER− | T2/3.9 | 3.1/3.52 | 2.1 | ACT | 1 |
| NIR034 | 35 | IDC | High (8) | ER + PR + HER2− | T2/3.1 | 1.2/2.953 | 1.0 | ACT | 2 |
| NIR038 | 44 | IDC | Intermed (5) | ER + PR + HER2− | T3/2.0 | 2.0/4.024 | 1.9 | ACT | 3 |
| NIR041 | 48 | ILC | Intermed (5) | ER + PR + HER− | T3/4.5 | 4.1/4.251 | 3.9 | ACT | 1 |
| NIR001 | 62 | IDC | High (8) | ER + PR + HER2 + | T2/1.2 | 0.0/0.0 | 0.0 | TCHP | 5 |
| NIR003 | 48 | IMC | Intermed (4) | ER + PR + HER2 + | T2/2.9 | 2.9/1.642 | 3.0 | TCHP | 1 |
| NIR007 | 42 | IDC | High (9) | ER- PR-HER2 + | T3/3.0 | 0.0/0.0 | 2.5 | TCHP | 5 |
| NIR010 | 39 | IDC | High (9) | ER + PR-HER2 + | T2/3.0 | 0.0/0.0 | 0.5 | TCHP | 5 |
| NIR018 | 44 | IDC | High (7) | ER-PR- HER2 + | T2/4.3 | 0.0/0.0 | 1.8 | TCHP | 5 |
| NIR019 | 37 | IDC | High (9) | ER + PR + Her2 + | T2/4.7 | 0.0/0.0 | 1.9 | TCHP | 5 |
| NIR022 | 30 | IDC | High (9) | ER-PR-HER2 + | T2/2.7 | 0.0/0.0 | 0.0 | TCHP | 5 |
| NIR029 | 52 | IDC | High (8) | ER + PR-HER2 + | T2/2.2 | 0.0/0.0 | 1.4 | TCHP | 5 |
| NIR032 | 38 | IDC | Intermed (6) | ER + PR-HER2 + | T3/1.9 | 0.0/0.0 | 1.2 | TCHP | 5 |
| NIR035 | 50 | IDC | High (7) | ER-PR-HER2 + | T1/2.5 | 0.0/0.0 | 0.0 | TCHP | 5 |
| NIR040 | 34 | IDC | High (7) | ER + PR + HER + | T2/4.8 | 0.2/1.277 | 0.8 | TCHP | 4 |
| NIR004 | 50 | IDC | High (9) | ER-PR-HER2− | T3/2.0 | 0.0/0.0 | 1.6 | CarboT | 5 |
| NIR009 | 38 | IDC | High (8) | ER-PR + HER-PR + HER2− | T2/1.4 | 0.0/0.0 | 0.0 | CarboT | 5 |
| NIR016 | 53 | IDC | High (9) | ER + 2PR-HER2− | T2/2.3 | 0.0/0.0 | 1.1 | CarboT | 5 |
| NIR020 | 48 | IDC | High (7) | ER-PR-HER2− | T2/2.7 | 0.15/1.899 | 1.9 | CarboT | 3 |
| NIR030 | 71 | IDC | High (9) | ER-PR-HER2− | T2/3.8 | 0.9/2.045 | 1.8 | CarboT | 2 |
| NIR031 | 24 | IDC | High (9) | ER-PR-HER2− | T3/3.4 | 0.0/0.0 | 0.5 | CarboT-AC | 5 |
| NIR012 | 49 | IDC | High (9) | ER- PR-HER2− | T2/2.2 | 0.0/0.0 | 2.3 | ACP | 5 |
| NIR028 | 39 | IDC | High (8) | ER-PR-HER2− | T2/2.8 | 2.5/3.82 | 2.4 | ACP | 3 |
| NIR013 | 52 | IDC | High (9) | ER + PR-HER2 + | T3/6.8 | 1.3/1.59 | n/a3 | PLT | 3 |
| NIR033 | 56 | IDC/ILC | High (9) | ER + PR-HER2 + | T2/4.1 | 1.1/1.561 | 2.4 | PLT | 3 |
| NIR036 | 57 | IDC | High (8) | ER + PR + HER2 + | T2/2.2 | 0.1/0.598 | 1.4 | PLT | 4 |
| NIR037 | 43 | IDC | High (7) | ER + PR + HER2 + | T1/2.3 | 0.0/0.0 | 1.3 | PLT | 5 |
| NIR039 | 66 | IDC | Intermed (5) | ER + PR + HER2− | T2/3.1 | 1.5/3.222 | n/a3 | Anastrazole | 1 |
IDC invasive ductal carcinoma, IMC invasive mucinous carcinoma, ILC invasive lobular carcinoma, TCHP docetaxel, carboplatin, trastuzumab, and pertuzumab, ACT AC (Doxorubicin hydrochloride and cyclophosphamide) every two weeks followed by weekly paclitaxel (Taxol) for 12 weeks, CarboT carboplatin (paraplatin) and docetaxel (taxotere), ClinicalTrials.gov Identifier: NCT02124902, ACP atezolizumab carboplatin paclitaxel ClinicalTrials.gov Identifier: NCT02883062, PLT Palbociclib Letrozole Trastuzumab ClinicalTrials.gov Identifier: NCT02907918, CarboT-AC carboplatin and docetaxel for four cycles followed by doxorubicin (adriamycin) / cyclophosphamide
Nottingham Grade: 1–3 low, 4–6 intermediate, 7–9 high
Initial receptor report from outside hospital was TNBC and corrected later as ER +
Surgery earlier than scheduled